Effect of ezetimibe/simvastatin vs atorvastatin on lowering levels of LDL-C and non–HDL-C, ApoB, and hs-CRP in patients with type 2 diabetes

This publication has 30 references indexed in Scilit:

• Relationship of Apolipoprotein B Levels to the Number of Risk Factors for Metabolic Syndrome
  Journal of Investigative Medicine, 2007
• AHA/ACC Guidelines for Secondary Prevention for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2006 Update
  Circulation, 2006
• Management of Dyslipidemia in Diabetes
  Cardiology in Review, 2006
• Apolipoproteins as markers and managers of coronary risk
  QJM: An International Journal of Medicine, 2006
• Non–High-Density Lipoprotein Cholesterol: The Forgotten Therapeutic Target
  The American Journal of Cardiology, 2005
• Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial
  The Lancet, 2004
• Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines
  Circulation, 2004
• MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial
  The Lancet, 2003
• Effects of Insulin Resistance and Type 2 Diabetes on Lipoprotein Subclass Particle Size and Concentration Determined by Nuclear Magnetic Resonance
  Diabetes, 2003
• Low-Density Lipoprotein, Non-High-Density Lipoprotein, and Apolipoprotein B as Targets of Lipid-Lowering Therapy
  Circulation, 2002